MedTrace Logo

Autologous Transplant in HIV Patients (BMT CTN 0803)

NCT01141712 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2023-01-04

Study results available
· View outcomes & findings →

Summary

This study is a Phase II, multicenter trial assessing overall survival after autologous hematopoietic stem cell transplantation using a BEAM transplant regimen (carmustine, etoposide, cytarabine, melphalan) in lymphoma patients with HIV.

Conditions

Interventions

PROCEDURE

Autologous transplant

Participants will receive the BEAM conditioning regimen followed by autologous HCT.

DRUG

BCNU

Participants will receive BCNU 300 mg/m\^2 Day -6

DRUG

Etoposide

Participants will receive Etoposide 100 mg/m\^2 BID Days -5 to -2

DRUG

Cytarabine

Participants will receive Cytarabine 100 mg/m\^2 BID Days -5 to -2

DRUG

Melphalan

Participants will receive Melphalan 140 mg/m\^2 Day -1

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • National Cancer Institute (NCI)

    collaborator NIH

  • Blood and Marrow Transplant Clinical Trials Network

    collaborator NETWORK

  • National Marrow Donor Program

    collaborator OTHER

  • Medical College of Wisconsin

    lead OTHER

Principal Investigators

  • Mary Horowitz, MD · Center for International Blood and Marrow Transplant Research

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2015-05-31
Completion
2016-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01141712 on ClinicalTrials.gov